| Juvenile arthritis
Amjevita vs Humira
Side-by-side clinical, coverage, and cost comparison for juvenile arthritis.Deep comparison between: Amjevita vs Humira with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHumira has a higher rate of injection site reactions vs Amjevita based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Humira but not Amjevita, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Amjevita
Humira
At A Glance
SC injection
Every other week
TNF-alpha antagonist
SC injection
Every other week
TNF-alpha antagonist
Indications
- Rheumatoid Arthritis
- Juvenile arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
- Rheumatoid Arthritis
- Juvenile arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Chronic small plaque psoriasis
- Hidradenitis Suppurativa
- Uveitis
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis Adults: 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile arthritis, Uveitis (pediatric, >=2 years) Weight-based SC every other week: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), 40 mg (>=30 kg).
Crohn Disease (adults) 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29.
Crohn Disease (pediatric, >=6 years) Weight-based: 80 mg Day 1 / 40 mg Day 15 / 20 mg every other week (17 to <40 kg); 160 mg Day 1 / 80 mg Day 15 / 40 mg every other week (>=40 kg).
Ulcerative Colitis Adults: 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.
Psoriasis vulgaris, Uveitis (adults) 80 mg SC initial dose, then 40 mg every other week starting one week after the initial dose.
Hidradenitis Suppurativa (adults) 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Hidradenitis Suppurativa (adolescents >=12 years, >=30 kg) Weight-based: 80 mg Day 1 / 40 mg every other week from Day 8 (30 to <60 kg); 160 mg Day 1 / 80 mg Day 15 / 40 mg weekly or 80 mg every other week from Day 29 (>=60 kg).
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may increase to 40 mg every week or 80 mg every other week.
Juvenile arthritis, Uveitis (pediatric) Weight-based SC dosing every other week: 10 mg (10 kg to <15 kg), 20 mg (15 kg to <30 kg), or 40 mg (>=30 kg) for patients 2 years of age and older.
Crohn Disease 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29.
Ulcerative Colitis 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by 8 weeks (Day 57).
Chronic small plaque psoriasis, Uveitis 80 mg SC initial dose, then 40 mg every other week starting 1 week after the initial dose.
Hidradenitis Suppurativa 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Contraindications
—
—
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, sinusitis, headache, rash, nausea, urinary tract infection, flu syndrome, abdominal pain, back pain, hypertension.
Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, hypersensitivity reactions, hepatitis B virus reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, pyrexia, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, systemic vasculitis, deep vein thrombosis.
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, accidental injury, sinusitis, urinary tract infection, nausea, hyperlipidemia, abdominal pain, flu syndrome, hypercholesterolemia, back pain.
Serious Serious infections (pneumonia, septic arthritis, prosthetic and post-surgical infections, erysipelas, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, severe hepatic reactions including acute liver failure, new-onset lupus-like syndrome.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, lichenoid skin reaction, systemic vasculitis, deep vein thrombosis.
Pharmacology
Adalimumab-atto is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, inhibiting TNF-mediated inflammatory and immune responses; it also lyses surface TNF-expressing cells in vitro in the presence of complement and modulates downstream biological responses including adhesion molecule expression (ELAM-1, VCAM-1, ICAM-1).
Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha, blocking its interaction with the p55 and p75 cell surface TNF receptors and inhibiting TNF-mediated inflammatory and immune responses, including modulation of adhesion molecules responsible for leukocyte migration.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Amjevita
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Humira
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Amjevita
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humira
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (0/8)
Humana
Amjevita
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Humira
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Amjevita.
$5/momo
Humira Complete Savings CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AmjevitaView full Amjevita profile
HumiraView full Humira profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.